Comparison Between the Progostic Value of the Procalcitonin and the Platelet/Total Leukocytic Count Ratio in Sepsis
NCT ID: NCT06991686
Last Updated: 2025-06-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-09-27
Study Completion Date
2025-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What is already known on this subject? AND What does this study add? Sepsis is a complicated condition caused by a malfunction of the host's immune response to infection, which results in an uncontrollable inflammatory response and immunosuppression.
Sepsis is seen as a global health problem with significant economic effects .As a result, identifying prognostic and diagnostic biomarkers is critical in order to avoid adverse outcomes and reduce mortality by initiating treatment before irreversible damage occurs. A delay of one hour in sepsis treatment is thought to be associated with a 7-10 percent increase in sepsis-related death . As a result, many efforts have been made to find a viable biomarker for screening sepsis patients who are at a high risk of death.
Procalciotnin and platelet/leukocytic count ratio have been studied before but there are few studies comparing them.
Multiple studies have elucidated the benefits associated with the precursor molecule of calcitonin, specifically PCT, as a biomarker for sepsis.
In recent years, there has been a growing body of research indicating that platelets (PLT) and total leukocytic count are significant contributors to the inflammatory process. Previous research suggests a possible association between platelet/total leukocytic count ratio and sepsis mortality.
In this study will compare between the prognostic value of procalcitonin and the platelet/total leukocytic count ratio in sepsis.
AIM/ OBJECTIVES The aim of this prospective cross-sectional study was to compare the PCT level and the platelet/total leukocytic count ratio for survival prediction in patients with Sepsis.
METHODOLOGY:
* Type of Study: Prospective cross-sectional Study
* Study Setting: This study was conducted at Ain Shams University intensive care units.
* Study Period: Six months after approval of ethical committee of Faculty of Medicine, Ain Shams University or end of recruited sample size.
Sample Size:
Assuming an AUC for procalcitonin of 0.977 and that of platelet/total leukocytic count ratio of 0.944, a sample of 100 patients would be enough to detect such difference with 0.11 allowable difference between the 2 AUC, at 0.05 alpha error and 0.80 power of the test .
Ethical considerations
* The approval of the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University was obtained before starting work on the study.
* All data were considered confidential and weren't used outside this study without patient approval.
* Informed written consent was taken from all patients after explaining the study procedure in details.
Data collected and period of the study:
Clinical data and laboratory indicators, including gender, age, vital signs, past medical history such as hypertension and diabetes, SOFA score, APACHE II score, PLT, and PCT, were recorded within 24 hours of admission. Sepsis patients were observed and followed up for 28 days. Patient survival and death was recorded.
CBC was done every other day and serum procalcitonin was done every 72 hours for 28 days and the results were analysed and compared in correlation with patient's survivability.
Data management and analysis All data will be analyzed statistically. All data will be included in the SPSS software version 21. The appropriate statistical method will be used for analysis. Descriptive statistics such as mean, standard deviation and percentages will be used. Comparison of categorical data will be done using Chi-square test and for continuous data; unpaired "t" test will be used.
Sepsis is seen as a global health problem with significant economic effects .As a result, identifying prognostic and diagnostic biomarkers is critical in order to avoid adverse outcomes and reduce mortality by initiating treatment before irreversible damage occurs. A delay of one hour in sepsis treatment is thought to be associated with a 7-10 percent increase in sepsis-related death . As a result, many efforts have been made to find a viable biomarker for screening sepsis patients who are at a high risk of death.
Procalciotnin and platelet/leukocytic count ratio have been studied before but there are few studies comparing them.
Multiple studies have elucidated the benefits associated with the precursor molecule of calcitonin, specifically PCT, as a biomarker for sepsis.
In recent years, there has been a growing body of research indicating that platelets (PLT) and total leukocytic count are significant contributors to the inflammatory process. Previous research suggests a possible association between platelet/total leukocytic count ratio and sepsis mortality.
In this study will compare between the prognostic value of procalcitonin and the platelet/total leukocytic count ratio in sepsis.
AIM/ OBJECTIVES The aim of this prospective cross-sectional study was to compare the PCT level and the platelet/total leukocytic count ratio for survival prediction in patients with Sepsis.
METHODOLOGY:
* Type of Study: Prospective cross-sectional Study
* Study Setting: This study was conducted at Ain Shams University intensive care units.
* Study Period: Six months after approval of ethical committee of Faculty of Medicine, Ain Shams University or end of recruited sample size.
Sample Size:
Assuming an AUC for procalcitonin of 0.977 and that of platelet/total leukocytic count ratio of 0.944, a sample of 100 patients would be enough to detect such difference with 0.11 allowable difference between the 2 AUC, at 0.05 alpha error and 0.80 power of the test .
Ethical considerations
* The approval of the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University was obtained before starting work on the study.
* All data were considered confidential and weren't used outside this study without patient approval.
* Informed written consent was taken from all patients after explaining the study procedure in details.
Data collected and period of the study:
Clinical data and laboratory indicators, including gender, age, vital signs, past medical history such as hypertension and diabetes, SOFA score, APACHE II score, PLT, and PCT, were recorded within 24 hours of admission. Sepsis patients were observed and followed up for 28 days. Patient survival and death was recorded.
CBC was done every other day and serum procalcitonin was done every 72 hours for 28 days and the results were analysed and compared in correlation with patient's survivability.
Data management and analysis All data will be analyzed statistically. All data will be included in the SPSS software version 21. The appropriate statistical method will be used for analysis. Descriptive statistics such as mean, standard deviation and percentages will be used. Comparison of categorical data will be done using Chi-square test and for continuous data; unpaired "t" test will be used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelets to Lymphocytes Ratio in Sepsis
NCT05399225
Platelets to Lymphocytes Ratio Sepsis
UNKNOWN
CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients
NCT04049565
Sepsis
Morality
COMPLETED
Role of PCO2 Gap as Predictor of Clinical Outcome in ICU Septic Patients
NCT06256198
Sepsis
NOT_YET_RECRUITING
Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.
NCT07200817
Neutrophils to Lymphocytes
Platelets
Procalcitonin
+4 more
RECRUITING
Value of Laboratory Biomarkers in Prediction of Outcome in Septic Patients
NCT06338124
Sepsis
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
What is already known on this subject? AND What does this study add? Sepsis is a complicated condition caused by a malfunction of the host's immune response to infection, which results in an uncontrollable inflammatory response and immunosuppression.
Sepsis is seen as a global health problem with significant economic effects . As a result, identifying prognostic and diagnostic biomarkers is critical in order to avoid adverse outcomes and reduce mortality by initiating treatment before irreversible damage occurs. A delay of one hour in sepsis treatment is thought to be associated with a 7-10 percent increase in sepsis-related death . As a result, many efforts have been made to find a viable biomarker for screening sepsis patients who are at a high risk of death.
Procalciotnin and platelet/leukocytic count ratio have been studied before but there are few studies comparing them.
In this study will compare between the prognostic value of procalcitonin and the platelet/total leukocytic count ratio in sepsis.
1. INTRODUCTION/ REVIEW Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, characterized by hypotension, elevated lactate, or oliguria. It is a common disease in critically ill patients and a major cause of death in intensive care units (ICUs). Despite improved understanding and management of sepsis over the past few decades, the mortality rate remains high, ranging from 20% to 45%, and it is a prominent challenge facing modern medicine and a significant global disease burden.
Sepsis presents with a diverse range of clinical manifestations, and there is a lack of specific indicators for diagnosis and prognosis evaluation, and the disease progresses rapidly. As the condition worsens, there can be dysfunction of cellular metabolic processes, resulting in sepsis, multiple organ dysfunction syndrome, poor patient outcomes, and even death. Therefore, finding laboratory indicators that can quickly assist in diagnosing sepsis is one of the urgent problems to be solved in critical care medicine.
A number of physicians have conducted research on the importance of blood biomarkers, including C-reactive protein, procalcitonin (PCT), and lactate, in the early evaluation of sepsis and in predicting patient outcomes.
Multiple studies have elucidated the benefits associated with the precursor molecule of calcitonin, specifically PCT, as a biomarker for sepsis.
In recent years, there has been a growing body of research indicating that platelets (PLT) and total leukocytic count are significant contributors to the inflammatory process. Previous research suggests a possible association between platelet/total leukocytic count ratio and sepsis mortality.
Among all the sepsis biomarkers studied, complete blood count (CBC) metrics, including the platelet to total leukocytic count ratio , could be valuable tools . Undoubtedly, CBC has many advantages: (i) it is inexpensive, (ii) it has a quick turn-around time (TAT), (iii) it is accessible in all health centers, (iv) it is simple to perform, (v) clinicians regularly request CBC as part of patient management, and (vi) it is the most commonly ordered laboratory test in all medical settings, from the ICU to the emergency department (ED) Under inflammatory conditions, platelets (PLTs) have a role in promoting coagulation factor activation and cell aggregation, which can lead to host response dysregulation. When sepsis occurs, the inflammatory response of bacteria and platelets, endotoxin-mediated platelet activation, and the effects of circulating immune complexes can all lead to platelet reduction.Platelet reduction is one of the most common complications in sepsis patients, and it is negatively correlated with the severity of sepsis and mortality rates.
Procalcitonin (PCT) is a nonhormonal glycoprotein whose levels are positively correlated with the severity of bacterial infections. It has important clinical significance in predicting the prognosis of infectious diseases and is a marker of disease course and treatment success. A multicenter randomized controlled trial involving sepsis patients showed that using PCT to guide patient antibiotic use can significantly reduce infection-related adverse events, 28-day mortality, and hospitalization costs.
2. AIM/ OBJECTIVES The aim of this prospective cross-sectional study was to compare the PCT level and the platelet/total leukocytic count ratio for survival prediction in patients with Sepsis.
3. METHODOLOGY:
Patients and Methods/ Subjects and Methods/ Material and Methods
* Type of Study: Prospective cross-sectional Study
* Study Setting: This study was conducted at Ain Shams University intensive care units.
* Study Period: Six months after approval of ethical committee of Faculty of Medicine, Ain Shams University or end of recruited sample size.
Sample Size:
Assuming an AUC for procalcitonin of 0.977 and that of platelet/total leukocytic count ratio of 0.944, a sample of 100 patients would be enough to detect such difference with 0.11 allowable difference between the 2 AUC, at 0.05 alpha error and 0.80 power of the test.
Ethical considerations
o The approval of the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University was obtained before starting work on the study.
o All data were considered confidential and weren't used outside this study without patient approval.
o Informed written consent was taken from all patients after explaining the study procedure in details.
Study Tools and procedure:
All patients included in this study were subjected on admission to the followings:
A. History:
* Personal data: name, age and gender.
* Present history of medical condition.
* Past medical history including:
* Heart disease.
* Liver disease
* Renal disease
* Hypertension.
* Diabetes mellitus.
* Hematological disorder.
* Oncological disorder.
B. Clinical examination:
o Complete physical examination was done with emphasis on:
\- Vital signs: (heart rate, mean pressure, respiratory rate, temperature)
\- Mental status according to Glasgow Coma Score (GCS)
\- Chest examination.
\- Cardiac examination.
\- Abdominal examination.
B. Clinical risk stratification:
\- APACHE II score SOFA score
C. Laboratory investigations:
Were done on admission and daily during the period of the study and included:
\- Serum Na, K.
\- Urea, creatinine.
\- Random blood sugar.
\- C-reactive protein.
\- Complete blood picture (Hemoglobin, White blood count (TLC), Platelet count).
* Procalcitonin.
D. Radiological examination that helps to detect source of sepsis included:
* Chest X-ray.
* Ultrasound of the abdomen.
* CT abdomen with contrast.
* Echo.
E. Sepsis workup:
* Blood cultures from one central and two peripheral lines.
* Sputum culture or mini bronchio-alveolar lavage.
* Urine culture.
* Culture from a known source like abscess or tissue.
F. Management:
Management of all sepsis patients will be done according to the latest survival sepsis campaign guidelines including fluid resuscitation, vasopressor support and antimicrobial therapy.
G. Data collected and period of the study:
Clinical data and laboratory indicators, including gender, age, vital signs, past medical history such as hypertension and diabetes, SOFA score, APACHE II score, PLT, and PCT, were recorded within 24 hours of admission. Sepsis patients were observed and followed up for 28 days. Patient survival and death was recorded.
CBC was done every other day and serum procalcitonin was done every 72 hours for 28 days and the results were analysed and compared in correlation with patient's survivability.
Data management and analysis All data will be analyzed statistically. All data will be included in the SPSS software version 21. The appropriate statistical method will be used for analysis. Descriptive statistics such as mean, standard deviation and percentages will be used. Comparison of categorical data will be done using Chi-square test and for continuous data; unpaired "t" test will be used.
Sepsis is seen as a global health problem with significant economic effects . As a result, identifying prognostic and diagnostic biomarkers is critical in order to avoid adverse outcomes and reduce mortality by initiating treatment before irreversible damage occurs. A delay of one hour in sepsis treatment is thought to be associated with a 7-10 percent increase in sepsis-related death . As a result, many efforts have been made to find a viable biomarker for screening sepsis patients who are at a high risk of death.
Procalciotnin and platelet/leukocytic count ratio have been studied before but there are few studies comparing them.
In this study will compare between the prognostic value of procalcitonin and the platelet/total leukocytic count ratio in sepsis.
1. INTRODUCTION/ REVIEW Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, characterized by hypotension, elevated lactate, or oliguria. It is a common disease in critically ill patients and a major cause of death in intensive care units (ICUs). Despite improved understanding and management of sepsis over the past few decades, the mortality rate remains high, ranging from 20% to 45%, and it is a prominent challenge facing modern medicine and a significant global disease burden.
Sepsis presents with a diverse range of clinical manifestations, and there is a lack of specific indicators for diagnosis and prognosis evaluation, and the disease progresses rapidly. As the condition worsens, there can be dysfunction of cellular metabolic processes, resulting in sepsis, multiple organ dysfunction syndrome, poor patient outcomes, and even death. Therefore, finding laboratory indicators that can quickly assist in diagnosing sepsis is one of the urgent problems to be solved in critical care medicine.
A number of physicians have conducted research on the importance of blood biomarkers, including C-reactive protein, procalcitonin (PCT), and lactate, in the early evaluation of sepsis and in predicting patient outcomes.
Multiple studies have elucidated the benefits associated with the precursor molecule of calcitonin, specifically PCT, as a biomarker for sepsis.
In recent years, there has been a growing body of research indicating that platelets (PLT) and total leukocytic count are significant contributors to the inflammatory process. Previous research suggests a possible association between platelet/total leukocytic count ratio and sepsis mortality.
Among all the sepsis biomarkers studied, complete blood count (CBC) metrics, including the platelet to total leukocytic count ratio , could be valuable tools . Undoubtedly, CBC has many advantages: (i) it is inexpensive, (ii) it has a quick turn-around time (TAT), (iii) it is accessible in all health centers, (iv) it is simple to perform, (v) clinicians regularly request CBC as part of patient management, and (vi) it is the most commonly ordered laboratory test in all medical settings, from the ICU to the emergency department (ED) Under inflammatory conditions, platelets (PLTs) have a role in promoting coagulation factor activation and cell aggregation, which can lead to host response dysregulation. When sepsis occurs, the inflammatory response of bacteria and platelets, endotoxin-mediated platelet activation, and the effects of circulating immune complexes can all lead to platelet reduction.Platelet reduction is one of the most common complications in sepsis patients, and it is negatively correlated with the severity of sepsis and mortality rates.
Procalcitonin (PCT) is a nonhormonal glycoprotein whose levels are positively correlated with the severity of bacterial infections. It has important clinical significance in predicting the prognosis of infectious diseases and is a marker of disease course and treatment success. A multicenter randomized controlled trial involving sepsis patients showed that using PCT to guide patient antibiotic use can significantly reduce infection-related adverse events, 28-day mortality, and hospitalization costs.
2. AIM/ OBJECTIVES The aim of this prospective cross-sectional study was to compare the PCT level and the platelet/total leukocytic count ratio for survival prediction in patients with Sepsis.
3. METHODOLOGY:
Patients and Methods/ Subjects and Methods/ Material and Methods
* Type of Study: Prospective cross-sectional Study
* Study Setting: This study was conducted at Ain Shams University intensive care units.
* Study Period: Six months after approval of ethical committee of Faculty of Medicine, Ain Shams University or end of recruited sample size.
Sample Size:
Assuming an AUC for procalcitonin of 0.977 and that of platelet/total leukocytic count ratio of 0.944, a sample of 100 patients would be enough to detect such difference with 0.11 allowable difference between the 2 AUC, at 0.05 alpha error and 0.80 power of the test.
Ethical considerations
o The approval of the Scientific Research Ethics Committee at the Faculty of Medicine, Ain Shams University was obtained before starting work on the study.
o All data were considered confidential and weren't used outside this study without patient approval.
o Informed written consent was taken from all patients after explaining the study procedure in details.
Study Tools and procedure:
All patients included in this study were subjected on admission to the followings:
A. History:
* Personal data: name, age and gender.
* Present history of medical condition.
* Past medical history including:
* Heart disease.
* Liver disease
* Renal disease
* Hypertension.
* Diabetes mellitus.
* Hematological disorder.
* Oncological disorder.
B. Clinical examination:
o Complete physical examination was done with emphasis on:
\- Vital signs: (heart rate, mean pressure, respiratory rate, temperature)
\- Mental status according to Glasgow Coma Score (GCS)
\- Chest examination.
\- Cardiac examination.
\- Abdominal examination.
B. Clinical risk stratification:
\- APACHE II score SOFA score
C. Laboratory investigations:
Were done on admission and daily during the period of the study and included:
\- Serum Na, K.
\- Urea, creatinine.
\- Random blood sugar.
\- C-reactive protein.
\- Complete blood picture (Hemoglobin, White blood count (TLC), Platelet count).
* Procalcitonin.
D. Radiological examination that helps to detect source of sepsis included:
* Chest X-ray.
* Ultrasound of the abdomen.
* CT abdomen with contrast.
* Echo.
E. Sepsis workup:
* Blood cultures from one central and two peripheral lines.
* Sputum culture or mini bronchio-alveolar lavage.
* Urine culture.
* Culture from a known source like abscess or tissue.
F. Management:
Management of all sepsis patients will be done according to the latest survival sepsis campaign guidelines including fluid resuscitation, vasopressor support and antimicrobial therapy.
G. Data collected and period of the study:
Clinical data and laboratory indicators, including gender, age, vital signs, past medical history such as hypertension and diabetes, SOFA score, APACHE II score, PLT, and PCT, were recorded within 24 hours of admission. Sepsis patients were observed and followed up for 28 days. Patient survival and death was recorded.
CBC was done every other day and serum procalcitonin was done every 72 hours for 28 days and the results were analysed and compared in correlation with patient's survivability.
Data management and analysis All data will be analyzed statistically. All data will be included in the SPSS software version 21. The appropriate statistical method will be used for analysis. Descriptive statistics such as mean, standard deviation and percentages will be used. Comparison of categorical data will be done using Chi-square test and for continuous data; unpaired "t" test will be used.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
All Conditions Causing Sepsis
Pneumonia - Bacterial
Urinary Tract Infection Bacterial
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
OTHER
Study Time Perspective
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
blood sample for CBC and procalcitonin
Intervention Type
DIAGNOSTIC_TEST
blood sample
blood sample for procalcitonin and CBC
Intervention Type
DIAGNOSTIC_TEST
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age more than 21 years.
* Patients presented with sepsis defined as a suspected source of infection plus ≥2 of the following:
* Fever of \>38º or hypothermia \<36º
* Heart rate of \>90 beats/min
* Respiratory rate of \>20 breaths per minute or PaCO2 \<32 mmHg
* White blood cells \>12 x 109/cmm or \<4 x 109/cmm, or \>10% immature forms.
* Patients presented with severe sepsis defined as sepsis associated with secondary organ dysfunction.
* Patients presented with sepsis defined as a suspected source of infection plus ≥2 of the following:
* Fever of \>38º or hypothermia \<36º
* Heart rate of \>90 beats/min
* Respiratory rate of \>20 breaths per minute or PaCO2 \<32 mmHg
* White blood cells \>12 x 109/cmm or \<4 x 109/cmm, or \>10% immature forms.
* Patients presented with severe sepsis defined as sepsis associated with secondary organ dysfunction.
Exclusion Criteria
* Age less than 21 years.
* Patients with acute cerebro-vascular event.
* Patients on chemotherapy.
* Patients with malignant hematological disease.
* Patients with immunosuppression.
* Patients with active hemorrhage.
* Patients who had used anti-PLT drugs such as clopidogrel prior to admission.
* Patients with life threating medical comorbidities (e.g.intractable heart failure, hepatic encephalopathy).
* Patients diagnosed with heparin induced thrombocytopenia (HIT).
* Patients on medications that help reducing platelet count such as linezolid.
* Patients with acute cerebro-vascular event.
* Patients on chemotherapy.
* Patients with malignant hematological disease.
* Patients with immunosuppression.
* Patients with active hemorrhage.
* Patients who had used anti-PLT drugs such as clopidogrel prior to admission.
* Patients with life threating medical comorbidities (e.g.intractable heart failure, hepatic encephalopathy).
* Patients diagnosed with heparin induced thrombocytopenia (HIT).
* Patients on medications that help reducing platelet count such as linezolid.
Minimum Eligible Age
21 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Meidcine Ain Shams University
Cairo, , Egypt
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Egypt
References
Explore related publications, articles, or registry entries linked to this study.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Moller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247. doi: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2. No abstract available.
Reference Type
BACKGROUND
Shannon O. The role of platelets in sepsis. Res Pract Thromb Haemost. 2020 Dec 20;5(1):27-37. doi: 10.1002/rth2.12465. eCollection 2021 Jan.
Reference Type
BACKGROUND
Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011 Jan;9(1):71-9. doi: 10.1586/eri.10.154.
Reference Type
BACKGROUND
Kim H, Kim Y, Lee HK, Kim KH, Yeo CD. Comparison of the delta neutrophil index with procalcitonin and C-reactive protein in sepsis. Clin Lab. 2014;60(12):2015-21. doi: 10.7754/clin.lab.2014.140528.
Reference Type
BACKGROUND
de Souza DC, Machado FR. Epidemiology of Pediatric Septic Shock. J Pediatr Intensive Care. 2019 Mar;8(1):3-10. doi: 10.1055/s-0038-1676634. Epub 2018 Dec 28.
Reference Type
BACKGROUND
Huang M, Cai S, Su J. The Pathogenesis of Sepsis and Potential Therapeutic Targets. Int J Mol Sci. 2019 Oct 29;20(21):5376. doi: 10.3390/ijms20215376.
Reference Type
BACKGROUND
Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level. Crit Care Med. 2018 Dec;46(12):1889-1897. doi: 10.1097/CCM.0000000000003342.
Reference Type
BACKGROUND
Andersson P, Frigyesi A. High-sensitivity troponin T is an important independent predictor in addition to the Simplified Acute Physiology Score for short-term ICU mortality, particularly in patients with sepsis. J Crit Care. 2019 Oct;53:218-222. doi: 10.1016/j.jcrc.2019.06.018. Epub 2019 Jun 19.
Reference Type
BACKGROUND
Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017 Nov;34(11):2393-2411. doi: 10.1007/s12325-017-0622-8. Epub 2017 Oct 11.
Reference Type
BACKGROUND
Agnello L, Giglio RV, Bivona G, Scazzone C, Gambino CM, Iacona A, Ciaccio AM, Lo Sasso B, Ciaccio M. The Value of a Complete Blood Count (CBC) for Sepsis Diagnosis and Prognosis. Diagnostics (Basel). 2021 Oct 12;11(10):1881. doi: 10.3390/diagnostics11101881.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU MS 598/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
NCT04105400
UNKNOWN
Comparison the Value of Several Biomarkers of Sepsis
NCT01388725
COMPLETED
A Comparative Study Between Neutrophil/Lymphocyte Ratio and Lactate/Albumin Ratio as Predictive Inflammatory Markers for Sepsis
NCT07089524
RECRUITING
White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis
NCT03880305
UNKNOWN
N\L Ratio Versus L\A Ratio as a Predictor of Morbidity and Mortality in Sepsis and Septic Shock
NCT05825118
UNKNOWN
Serum Albumin Ratios Can Improve Sepsis Mortality Prediction
NCT06640504
COMPLETED
Sensitivity and Specificity of Leucocytes Subpopulation Versus Platelet Indices in Prediction of Clinical Outcome for Candidates With Sepsis. A Bi-centric Observational Clinical Trial
NCT06612307
NOT_YET_RECRUITING
The Prognostic Value of Lactate is Different Among Septic Patients
NCT04155060
COMPLETED
Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock
NCT05921825
UNKNOWN
Shock Indices Use for Early Mortality From Septic Shock
NCT05088109
UNKNOWN
Evaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis
NCT03506152
COMPLETED
a Novel Index for Tissue Perfusion in Predicting Outcome in Patients With Septic Shock
NCT05289388
UNKNOWN
A Prospective Observational Study of Sepsis
NCT05309889
UNKNOWN
Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients
NCT06915974
RECRUITING
NA
Measurement of Mass Change in Serum Albumin Compared to Serum Lactic Acid as Predictive Tool for Sepsis Prognosis in Non Surgical ICU Patients
NCT07289906
ACTIVE_NOT_RECRUITING
The Role of NLR in the Diagnosis and Prognosis of Sepsis
NCT05636202
COMPLETED
Early Identification and Effective Management of Pediatric Sepsis
NCT03996720
COMPLETED
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
NCT05229328
UNKNOWN
Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
NCT00934011
COMPLETED
NA
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
NCT03682003
UNKNOWN
Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department
NCT02898948
COMPLETED
Evaluation of the Prognostic Value of Immature Platelet Fraction
NCT07039227
ACTIVE_NOT_RECRUITING
Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis
NCT01995448
COMPLETED
A Clinical Trial of Procalcitonin-guided Antimicrobial Therapy in Sepsis
NCT03333304
COMPLETED
NA
Heparin Binding Protein as a Prognostic Biomarker of Sepsis Severity
NCT05610020
COMPLETED